C4X Discovery Holdings PLC Grant of options and Directors Dealing (6161I)
15 December 2020 - 4:14AM
UK Regulatory
TIDMC4XD
RNS Number : 6161I
C4X Discovery Holdings PLC
14 December 2020
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Grant of options and Directors Dealing
14 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces that a total of
600,000 options over ordinary shares of the Company were awarded
pursuant to the EMI 2014 Plan to certain employees, which includes
200,000 options each to Dr Clive Dix, Chief Executive Officer, Dr
Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial
Officer, as set out below.
Director Position Number of share Option exercise Total number
options awarded price per share of options
(pence) held
Dr Clive Chief Executive
Dix Officer 200,000 20 645,000
------------------ ----------------- ----------------- -------------
Dr Craig Chief Scientific
Fox officer 200,000 20 700,000
------------------ ----------------- ----------------- -------------
Chief Financial
Brad Hoy Officer 200,000 20 800,000
------------------ ----------------- ----------------- -------------
The options have an exercise price of 20 pence, being the
average 5-day VWAP of the ordinary shares to the 11 December 2020.
The options can be exercised at any time between three and 10 years
of them being granted.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name(s) Dr Clive Dix
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
Chief Executive Officer, Director
a) Position/status
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
------------------------------------------------------- -------------------------------------------------------
b) LEI 213800UHNL82E323O870
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of one penny (GBP0.01)
instrument each in the share capital of the Company
- EMI 2014 Plan
Identification code
ISIN GB00BQQ2RV18
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of o ptions over o rdinary s hares
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
20 p 20 0,000
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 14 December 2020
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Craig Fox
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
Chief Scientific Officer, Director
a) Position/status
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
------------------------------------------------------- -------------------------------------------------------
b) LEI 213800UHNL82E323O870
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of one penny (GBP0.01)
instrument each in the share capital of the Company
- EMI 2014 Plan
Identification code
ISIN GB00BQQ2RV18
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of o ptions over o rdinary s hares
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
20 p 20 0,000
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 14 December 2020
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------- -------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Brad Hoy
------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
Chief Financial Officer, Director
a) Position/status
------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
------------------------------------------------------- -------------------------------------------------------
b) LEI 213800UHNL82E323O870
------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of one penny (GBP0.01)
instrument each in the share capital of the Company
- EMI 2014 Plan
Identification code
ISIN GB00BQQ2RV18
------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Grant of o ptions over o rdinary s hares
------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
20 p 20 0,000
------------------------------------------------------- -------------------------------------------------------
d) Aggregated information
------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 14 December 2020
------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------- -------------------------------------------------------
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive
Drug Discovery engine by using cutting-edge technologies and
expertise to efficiently deliver best-in-class small-molecule
medicines to clinical partners for the benefit of patients. The
Company's business model focuses on replenishing big pharma
discovery pipelines and driving returns through revenue generating
pre-clinical licensing deals. In 2018, C4XD successfully
out-licensed a pre-clinical programme in addictive disorders to
Indivior in a deal worth up to $294m, which is now in a Phase I
clinical study.
C4XD has a state-of-the-art suite of proprietary technologies
across the Drug Discovery process and accesses further innovative
capabilities and expertise through its growing network of partners.
The Company is actively advancing its diverse pre-clinical
discovery portfolio which is focused on inflammation,
neurodegeneration and oncology (including immuno-oncology).
Opportunities to maximise value from the portfolio are proactively
driven by C4XD's commercial division. The Company is led by a
highly experienced management team and Board who have delivered
significant value creation within the healthcare sector.
For additional information please go to:
www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUSABRROUUAAA
(END) Dow Jones Newswires
December 14, 2020 12:14 ET (17:14 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024